PT - JOURNAL ARTICLE AU - Yujing Song AU - Yuxuan Ye AU - Shiuan-Haur Su AU - Andrew Stephens AU - Tao Cai AU - Meng-Ting Chung AU - Meilan Han AU - Michael W. Newstead AU - David Frame AU - Benjamin H. Singer AU - Katsuo Kurabayashi TI - A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring AID - 10.1101/2020.06.15.20131870 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.15.20131870 4099 - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131870.short 4100 - http://medrxiv.org/content/early/2020/06/17/2020.06.15.20131870.full AB - Despite widespread concern for cytokine storms leading to severe morbidity in COVID-19, rapid cytokine assays are not routinely available for monitoring critically ill patients. We report the clinical application of a machine learning-based digital protein microarray platform for rapid multiplex quantification of cytokines from critically ill COVID-19 patients admitted to the intensive care unit (ICU) at the University of Michigan Hospital. The platform comprises two low-cost modules: (i) a semi-automated fluidic dispensing/mixing module that can be operated inside a biosafety cabinet to minimize the exposure of technician to the virus infection and (ii) a 12-12-15 inch compact fluorescence optical scanner for the potential near-bedside readout. The platform enabled daily cytokine analysis in clinical practice with high sensitivity (<0.4pg/mL), inter-assay repeatability (∼10% CV), and near-real-time operation with a 10min assay incubation. A cytokine profiling test with the platform allowed us to observe clear interleukin −6 (IL-6) elevations after receiving tocilizumab (IL-6 inhibitor) while significant cytokine profile variability exists across all critically ill COVID-19 patients and to discover a weak correlation between IL-6 to clinical biomarkers, such as Ferritin and CRP. Our data revealed large subject-to-subject variability in a patient’s response to anti-inflammatory treatment for COVID-19, reaffirming the need for a personalized strategy guided by rapid cytokine assays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the funding support from the National Institute of Health K08NS101054 (B.H.S), the National Science Foundation CBET1931905 (K.K.), the University of Michigan COVID-19 Response Innovation Grant (B.H.S and K.K), and the University of Michigan Precision Health Scholars Grant (Y.S.). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Michigan Institutional Review Board (HUM00179668) and patients or their surrogates provided informed consent for the investigational use of this test. Patients with positive SARS-CoV-2 test via PCR and respiratory failure requiring hospitalization in the intensive care unit for heated high flow oxygen or mechanical ventilation were eligible for enrollment. Subjects were approached at the request of treating teams at any point in their disease course after intensive care unit admission. Due to restrictions on patient contact during the COVID19 pandemic, samples were drawn by the subjects' nurse with routine clinical labs in a serum separator tube and sent to the clinical specimen processing area, where they were centrifuged, aliquoted, and kept at 4 Degree C until analysis. IL-6, TNF-α, IL-1β, and IL-10 were measured and results were posted to the patient's chart the same day. Ferritin and C-reactive protein (CRP) measurements made during routine clinical care were recorded if available from a sample within 24 hours of the cytokine measurement.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIf requested, the authors will make data available for sharing with qualified parties, so long as such a request does not compromise intellectual property interests, invade subject privacy, betray confidentiality, or precede data duration. Data that are shared will include standards and notations needed to interpret the data, following commonly accepted practices in the field. Data will be shared by mailing a CD or USB memory with the data to the requestor from the authors' administrator.